Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Stabilization of p21 by mTORC1/4E-BP1 predicts clinical outcome of head and neck cancers

  • LLanos, Susana
  • García-Pedrero, Juana M
  • Morgado-Palacin, Lucia
  • Rodrigo, Juan P
  • Serrano Marugan, Manuel
The levels, regulation and prognostic value of p21 in head and neck squamous cell carcinomas (HNSCC) has been puzzling for years. Here, we report a new mechanism of regulation of p21 by the mTORC1/4E-BP1 pathway. We find that non-phosphorylated 4E-BP1 interacts with p21 and induces its degradation. Accordingly, hyper-activation of mTORC1 results in phosphorylation of 4E-BP1 and stabilization of p21. In HNSCC, p21 levels strongly correlate with mTORC1 activity but not with p53 status. Finally, clinical data indicate that HNSCC patients with p21 and phospho-S6-double-positive tumours present a better disease-specific survival. We conclude that over-activation of the mTORC1/4E-BP1/p21 pathway is a frequent and clinically relevant alteration in HNSCC.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Signalling mechanisms and agricultural applications of (Z)-3-Hexenyl Butyrate-mediated stomatal closure

  • Payá, Celia
  • Jordá, Lucía
  • Belda Palazón, Borja
  • Vera-Sirera, Francisco|||0000-0002-1143-7692
  • Pérez, J|||0000-0001-9448-0700
  • Rodrigo Bravo, Ismael|||0000-0002-8994-6112
  • Belles Albert, José Mª|||0000-0003-0362-9616
  • López-Gresa, María Pilar|||0000-0001-9251-0160
  • Lisón, Purificación|||0000-0002-1662-8084
[EN] Biotic and abiotic stresses can severely limit crop productivity. In response to drought, plants close stomata to prevent water loss. Furthermore, stomata are the main entry point for several pathogens. Therefore, the development of natural products to control stomata closure can be considered a sustainable strategy to cope with stresses in agriculture. Plants respond to different stresses by releasing volatile organic compounds. Green leaf volatiles, which are commonly produced across different plant species after tissue damage, comprise an important group within volatile organic compounds. Among them, (Z)-3-hexenyl butyrate (HB) was described as a natural inducer of stomatal closure, playing an important role in stomatal immunity, although its mechanism of action is still unknown. Through different genetic, pharmacological, and biochemical approaches, we here uncover that HB perception initiates various defence signalling events, such as activation of Ca2+ permeable channels, mitogen-activated protein kinases, and production of Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-mediated reactive oxygen species. Furthermore, HB-mediated stomata closure was found to be independent of abscisic acid biosynthesis and signalling. Additionally, exogenous treatments with HB alleviate water stress and improve fruit productivity in tomato plants. The efficacy of HB was also tested under open field conditions, leading to enhanced resistance against Phytophthora spp. and Pseudomonas syringae infection in potato and tomato plants, respectively. Taken together, our results provide insights into the HB signalling transduction pathway, confirming its role in stomatal closure and plant immune system activation, and propose HB as a new phytoprotectant for the sustainable control of biotic and abiotic stresses in agriculture., This work was supported by grant PID2020-116765RB-I00 funded by MCIN/AEI/10.13039/501100011033/, grant PID2021-126006OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by "ERDFA way of making Europe" to L.J., and grant CDTI/IDI-20200721 funded by MCIN/Quimicas Meristem S.L. Work in the lab is also supported by grant PROMETEU/2021/056 from Generalitat Valenciana. C.P. was a recipient of a predoctoral contract from the Generalitat Valenciana (ACIF/2019/187), J.P.-P. is a recipient of a predoctoral contract from the Ministerio de Universidades e Investigacion (FPU21/00259), and B.B.-P. was a recipient of a postdoctoral contract from the Ministerio de Universidades (Ayuda Maria Zambrano para la Atraccion de Talento Internacional).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Metabolic crosstalk between hydroxylated monoterpenes and salicylic acid in tomato defense response against bacteria

  • Pérez, J|||0000-0001-9448-0700
  • Campos Beneyto, Laura|||0000-0002-5426-5966
  • RODRIGUEZ-CONCEPCION, Manuel|||0000-0002-1280-2305
  • ANA ESPINOSA RUIZ
  • Rodrigo Bravo, Ismael|||0000-0002-8994-6112
  • Belles Albert, José Mª|||0000-0003-0362-9616
  • López-Gresa, María Pilar|||0000-0001-9251-0160
  • Lisón, Purificación|||0000-0002-1662-8084
  • Minguillón, Samuel
  • Kabbas-Piñango, Elías
  • Payá, Celia
[EN] Hydroxylated monoterpenes (HMTPs) are differentially emitted by tomato (Solanum lycopersicum) plants resisting bacterial infection. We have studied the defensive role of these volatiles in the tomato response to bacteria, whose main entrance is through stomatal apertures. Treatments with some HMTPs resulted in stomatal closure and pathogenesis-related protein 1 (PR1) induction. Particularly, alpha-terpineol induced stomatal closure in a salicylic acid (SA) and abscisic acid-independent manner and conferred resistance to bacteria. Interestingly, transgenic tomato plants overexpressing or silencing the monoterpene synthase MTS1, which displayed alterations in the emission of HMTPs, exhibited changes in the stomatal aperture but not in plant resistance. Measures of both 2-C-methyl-D-erythritol-2,4-cyclopyrophosphate (MEcPP) and SA levels revealed competition for MEcPP by the methylerythritol phosphate (MEP) pathway and SA biosynthesis activation, thus explaining the absence of resistance in transgenic plants. These results were confirmed by chemical inhibition of the MEP pathway, which alters MEcPP levels. Treatments with benzothiadiazole (BTH), a SA functional analog, conferred enhanced resistance to transgenic tomato plants overexpressing MTS1. Additionally, these MTS1 overexpressors induced PR1 gene expression and stomatal closure in neighboring plants. Our results confirm the role of HMTPs in both intra- and interplant immune signaling and reveal a metabolic crosstalk between the MEP and SA pathways in tomato plants.; Hydroxylated monoterpenes play an important role in both intra- and interplant immune signaling in tomato against bacterial infection., This work was supported by grant PID2020-116765RB-I00 funded by MCIN/AEI/10.13039/501100011033/ and grant PROMETEU/2021/056 by Generalitat Valenciana. C.P. was a recipient of a predoctoral contract of the Generalitat Valenciana (ACIF/2019/187), and J.P.-P. is a recipient of a JAEINT_21_02081 of the Consejo Superior de Investigaciones Cientificas and a predoctoral contract of the Ministerio de Universidades (FPU21/00259).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models

  • Vinueza-Gavilanes, Rodrigo
  • Bravo-González, Jorge Juan
  • Basurco, Leyre
  • Boncristiani, Chiara
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Marcilla, Irene
  • Pérez Mediavilla, Alberto
  • Luquin, María Rosario
  • Vales, Africa
  • González-Aseguinolaza, Gloria
  • Aymerich, María Soledad
  • Aragón, Tomás
  • Arrasate, Montserrat
Synucleinopathies are a group of neurodegenerative diseases without effective treatment characterized by the abnormal aggregation of alpha-synuclein (aSyn) protein. Changes in levels or in the amino acid sequence of aSyn (by duplication/triplication of the aSyn gene or point mutations in the encoding region) cause familial cases of synucleinopathies. However, the specific molecular mechanisms of aSyn-dependent toxicity remain unclear. Increased aSyn protein levels or pathological mutations may favor abnormal protein-protein interactions (PPIs) that could either promote neuronal death or belong to a coping response program against neurotoxicity. Therefore, the identification and modulation of aSyn-dependent PPIs can provide new therapeutic targets for these diseases. To identify aSyn-dependent PPIs we performed a proximity biotinylation assay based on the promiscuous biotinylase BioID2. When expressed as a fusion protein, BioID2 biotinylates by proximity stable and transient interacting partners, allowing their identification by streptavidin affinity purification and mass spectrometry. The aSyn interactome was analyzed using BioID2-tagged wild-type (WT) and pathological mutant E46K aSyn versions in HEK293 cells. We found the 14-3-3 epsilon isoform as a common protein interactor for WT and E46K aSyn. 14‐3-3 epsilon correlates with aSyn protein levels in brain regions of a transgenic mouse model overexpressing WT human aSyn. Using a neuronal model in which aSyn cell-autonomous toxicity is quantitatively scored by longitudinal survival analysis, we found that stabilization of 14‐3-3 protein-proteins interactions with Fusicoccin-A (FC-A) decreases aSyn-dependent toxicity. Furthermore, FC-A treatment protects dopaminergic neuronal somas in the substantia nigra of a Parkinson's disease mouse model. Based on these results, we propose that the stabilization of 14‐3-3 epsilon interaction with aSyn might reduce aSyn toxicity, and highlight FC-A as a potential therapeutic compound for synucleinopathies., This work was supported by the Navarra Government (3/2019 , PC060-061 and PC192-193), the Spanish Government ISCIII-FEDER PI20/01063 and PI21/00259 and the Fundación para la Investigación Médica Aplicada (FIMA) . R.V-G was supported by a postdoctoral contract from the Navarra Government (PC192-193), J.B. by the Investigación Biomédica AC 2020 Predoctoral Fellowships from CIMA University of Navarra , C·B was supported by University of Milan with Students Erasmus+ Scholarships a.y. 2018/2019 and L. B. by a FPU predoctoral fellowship FPU018/02244 .
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Clinical predictors and psychosocial risk factors of suicide attempt severity

  • González-Ortega, Itxaso
  • Díaz-Marsá, Marina
  • Lopez-Peña, Purificación
  • Fernández-Sevillano, Jessica
  • Andreo-Jover, Jorge
  • Bobes, Julio
  • Bravo-Ortiz, M.
  • Cebriá, Ana Isabel
  • Crespo-Facorro, Benedicto
  • Torre-Luque, Alejandro de la
  • Elices, Matilde
  • Fernández-Rodrigues, Verónica
  • Garrido-Torres, Nathalia
  • Grande, Iria
  • Palao-Tarrero, Ángela
  • Pemau, Andrés
  • Roberto, Natalia
  • Ruiz‐Veguilla, Miguel
  • Seijo-Zazo, Elisa
  • Alberich, Susana
  • González-Pinto, Ana
  • Pérez, Víctor
[Background] Suicide attempts are an important predictor of completed suicide and may differ in terms of severity of medical consequences or medical lethality. There is little evidence on serious suicide attempt (SSA) and very few studies have compared SSA with non-SSA., [Objective] The aim of this multisite, coordinated, cohort study was to analyze the role of clinical variables and the sociodemographic and psychological risk factors of SSA., [Method] In this multisite, coordinated, cohort study, 684 participants (222 for the mild suicide attempt group, 371 for the moderate suicide attempt group and 91 for the SSA group) were included in the study. Ordinal regression models were performed to analyze the predictor variables of SSA., [Results] Early physical abuse (OR = 1.231) and impulsivity (OR = 1.036) were predictors of SSA, while depressive symptoms were associated with a lower risk of SSA., [Conclusion] Environmental and psychological factors as physical abuse and impulsivity are related with severe suicide severity. These findings will help to develop strategies to prevent suicide and may be considered for the treatment and management of suicide., This study was funded by the Spanish Ministry of Economy and Competitiveness through the Carlos III Health Institute (ISCIII) and the European Regional Development Fund (ERDF): Complutense University of Madrid (PI20/00259), Mar Institute of Medical Research (IMIM), Parc de Salut Mar (PI19/00236), University of Oviedo (PI19/01027), Hospital Clínico San Carlos (PI19/01256), Araba University Hospital (PI19/00569), La Paz Institute for Health Research (IdiPAZ) (PI19/00941), Hospital Universitari Parc Taulí (PI19/01484), Hospital Clínic of Barcelona (PI19/000954), Hospital Virgen del Rocío (PI19/00685). Dr. Bobes has received partial support from the Government of the Principality of Asturias PCTI-2021-2023 IDI/2021/111, the Fundación para la Investigación e Innovación Biosanitaria del Principado de Asturias (FINBA), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovación. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. González-Pinto thanks the support of the Spanish Ministry of Economy and Competitiveness through the Carlos III Health Institute (ISCIII) and the European Regional Development Fund (ERDF) (PI18/01055, PI21/00713); the Foundation for Health Innovation and Research (BIOEF); the Networking Centre for Biomedical Research in Mental Health (CIBERSAM), the Basque Government [grant number 2017111104] and the University of the Basque Country [grant number 321218ELCY]. The psychiatric research department in Araba University Hospital is supported by the Stanley Research Foundation [grant number 03-RC-003]. Dr. Grande thanks the support of the Spanish Ministry of Science and Innovation (MCIN) (PI19/00954) integrated into the Plan Nacional de I + D + I and cofinanced by the ISCIII-Subdirección General de Evaluación y Fondos Europeos de la Unión Europea (FEDER, FSE, Next Generation EU/Plan de Recuperación Transformación y Resiliencia_PRTR); the Instituto de Salud Carlos III; the Networking Centre for Biomedical Research in Mental Health (CIBERSAM); and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2017 SGR 1365), CERCA Programme/Generalitat de Catalunya as well as the Fundació Clínic per la Recerca Biomèdica (Pons Bartran 2022-FRCB_PB1_2022)., Peer reviewed
Repositorio Institucional de la Universidad de Burgos (RIUBU)
Publicación Artículo científico (JournalArticle)

LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus

  • Cobo Vuilleumier, Nadia .
  • Lorenzo, Petra Isabel .
  • García Rodríguez, Noelia .
  • Gracia Herrera-Gómez, Irene de .
  • Fuente Martín, Esther .
  • López Noriega, Livia
  • Mellado Gil, José Manuel .
  • Romero Zerbo, Silvana-Yanina .
  • Baquié, Mathurin .
  • Lachaud, Christian Claude .
  • Stifter, Katja .
  • Perdomo Hernández, Germán M.
  • Bugliani, Marco .
  • Tata, Vincenzo de .
  • Bosco, Domenico .
  • Parnaud, Geraldine .
  • Pozo, David .
  • Hmadcha, Abdelkrim .
  • Florido, Javier P. .
  • Toscano, Miguel G. .
  • Haan, Peter de .
  • Schoonjans, Kristina .
  • Sánchez Palazón, Luis .
  • Marchetti, Piero .
  • Schirmbeck, Reinhold .
  • Martín Montalvo, Alejandro .
  • Meda, Paolo .
  • Soria, Bernat .
  • Bermúdez Silva, Francisco Javier .
  • St-Onge16, Luc .
  • Gauthier, Benoit R. .
Type 1 diabetes mellitus (T1DM) is due to the selective destruction of islet beta cells by immune cells. Current therapies focused on repressing the immune attack or stimulating beta cell regeneration still have limited clinical efficacy. Therefore, it is timely to identify innovative targets to dampen the immune process, while promoting beta cell survival and function. Liver receptor homologue-1 (LRH-1) is a nuclear receptor that represses inflammation in digestive organs, and protects pancreatic islets against apoptosis. Here, we show that BL001, a small LRH-1 agonist, impedes hyperglycemia progression and the immune-dependent inflammation of pancreas in murine models of T1DM, and beta cell apoptosis in islets of type 2 diabetic patients, while increasing beta cell mass and insulin secretion. Thus, we suggest that LRH-1 agonism favors a dialogue between immune and islet cells, which could be druggable to protect against diabetes mellitus., the Juvenile Diabetes Research Foundation (17-2013-372 to B.R.G.), the Consejeria de Salud, Fundacion Publica Andaluza Progreso y Salud, Junta de Andalucia (PI-0727-2010 to B.R.G. and P10CTS6505 to B.S.), Consejeria de Economia, Innovacion y Ciencia (P10.CTS.6359 to B.R.G.), the Ministerio de Economia y Competidividad cofunded by Fondos FEDER (PI10/00871, PI13/00593, and BFU2017-83588-P to B.R.G.; PI14/01015, RD12/0019/0028, and RD16/0011/0034 to B.S.; PI16/00259 to A. H.) and Deutsche Forschungsgemeinschaft (GRK-1789 ´CEMMA´ and DFG SCHI-505/ 6-1 to R.S.). Special thanks to the families of the DiabetesCero Foundation that graciously supported this work (to B.R.G.). A.M.M. is a recipient of a Miguel Servet grant (CP14/ 00105) from the Instituto de Salud Carlos III co-funded by Fondos FEDER whereas E.F. M. is a recipient of a Juan de la Cierva Fellowship. I.G.H.G. is supported by a fellowship from Amarna Therapeutics. In some instances, human islets were procured through the European Consortium for Islet Transplantation funded by Juvenile Diabetes Research Foundation (3-RSC-2016-162-I-X).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

  • Ros Montañá, Fco. Javier
  • Fernández, Jose
  • Moreno-Cárdenas, Ana Belén
  • Arenillas Lallana, Carlota
  • Fasani, Roberta
  • Garcia Rodriguez, Ariadna
  • Gonzalo-Ruiz, Javier
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Pérez López, Raquel
  • Tabernero, Josep
  • De Almeida Toledo, Rodrigo
  • Comas Navarro, Raquel
  • Dienstmann, Rodrigo
  • Bernatowicz, Kinga
  • Piris-Giménez, Alejandro
  • Elez Fernandez, Mª Elena
  • Villacampa Javierre, Guillermo
Colorectal cancer; Predictive markers; Tumour biomarkers, Cáncer colorrectal; Marcadores predictivos; Biomarcadores tumorales, Càncer colorrectal; Marcadors predictius; Biomarcadors tumorals, Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients., VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 /501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundación AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diacylglycerol is required for the formation of COPI vesicles in the Golgi-to-ER transport pathway

  • Fernández Ulibarri, Inés
  • Vilella, Montserrat
  • Lázaro Diéguez, Francisco
  • Sarri Plans, Elisabet
  • Martínez, Susana E.
  • Jiménez, Nuria
  • Claro Izaguirre, Enrique|||0000-0002-7592-7906
  • Mérida, Isabel
  • Burger, Koert N. J.
  • Egea, Gustavo|||0000-0001-5242-150X
Diacylglycerol is necessary for trans-Golgi network (TGN) to cell surface transport, but its functional relevance in the early secretory pathway is unclear. Although depletion of diacylglycerol did not affect ER-to-Golgi transport, it led to a redistribution of the KDEL receptor to the Golgi, indicating that Golgi-to-ER transport was perturbed. Electron microscopy revealed an accumulation of COPI-coated membrane profiles close to the Golgi cisternae. Electron tomography showed that the majority of these membrane profiles originate from coated buds, indicating a block in membrane fission. Under these conditions the Golgi-associated pool of ARFGAP1 was reduced, but there was no effect on the binding of coatomer or the membrane fission protein CtBP3/BARS to the Golgi. The addition of 1,2-dioctanoyl-sn-glycerol or the diacylglycerol analogue phorbol 12,13-dibutyrate reversed the effects of endogenous diacylglycerol depletion. Our findings implicate diacylglycerol in the retrograde transport of proteins from Golgi to the ER and suggest that it plays a critical role at a late stage of COPI vesicle formation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Novel Role for Nanog As An Early Cancer Risk Marker in Patients with Laryngeal Precancerous Lesions

  • Rodrigo, Juan P.
  • Villaronga, M. Ángeles
  • Menéndez, Sofía T.
  • Hermida-Prado, Francisco
  • Quer, Miquel|||0000-0003-2563-6729
  • Vilaseca, Isabel|||0000-0003-4399-5522
  • Allonca, Eva|||0000-0002-2532-5421
  • Pedregal Mallo, Daniel
  • Astudillo, Aurora
  • García-Pedrero, Juana María|||0000-0002-5891-9488
NANOG is a master regulator of embryonic stem cell pluripotency, found to be frequently aberrantly expressed in a variety of cancers, including laryngeal carcinomas. This study investigates for the first time the role of NANOG expression in early stages of laryngeal tumourigenesis and its potential utility as cancer risk marker. NANOG protein expression was evaluated by immunohistochemistry using two large independent cohorts of patients with laryngeal precancerous lesions, and correlated with clinicopathological parameters and laryngeal cancer risk. NANOG expression was detected by immunohistochemistry in 49 (60%) of 82 laryngeal dysplasias, whereas expression was negligible in patient-matched normal epithelia. Strong NANOG expression was found in 22 (27%) lesions and was established as cut-off point, showing the most robust association with laryngeal cancer risk (P = 0.003) superior to the histological classification (P = 0.320) the current gold standard in the clinical practice. Similar trends were obtained using a multicenter validation cohort of 86 patients with laryngeal dysplasia. Our findings uncover a novel role for NANOG expression in laryngeal tumourigenesis, and its unprecedented application as biomarker for cancer risk assessment.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

  • Ros Montañá, Fco. Javier
  • Fernández, Jose
  • Moreno-Cárdenas, Ana Belén
  • Arenillas Lallana, Carlota
  • Fasani, Roberta
  • Garcia Rodriguez, Ariadna
  • Gonzalo-Ruiz, Javier
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Pérez López, Raquel
  • Tabernero, Josep
  • De Almeida Toledo, Rodrigo
  • Comas Navarro, Raquel
  • Dienstmann, Rodrigo
  • Bernatowicz, Kinga
  • Piris-Giménez, Alejandro
  • Elez Fernandez, Mª Elena
  • Villacampa Javierre, Guillermo
Colorectal cancer; Predictive markers; Tumour biomarkers, Cáncer colorrectal; Marcadores predictivos; Biomarcadores tumorales, Càncer colorrectal; Marcadors predictius; Biomarcadors tumorals, Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients., VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 /501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundación AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).